Black Diamond Therapeutics BDTX Income Statement (2018-2026)

NASDAQ BDTX
$2.20 +0.05 (+2.56%)
As of: Aug 21, 2026 · 11:35 AM EDT
Income Statement Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Revenue & cost
Revenue (Quarter)
70.00M
Operating items
Research & Development (Quarter)
27.63M19.66M17.79M16.20M15.85M14.61M14.75M13.15M16.15M15.29M13.54M12.56M12.91M12.30M10.51M9.32M7.44M6.30M7.00M7.39M
Selling, General & Administrative (Quarter)
7.74M6.42M7.89M6.98M6.28M7.24M6.81M6.88M7.86M5.57M6.70M9.57M5.22M5.98M4.96M4.10M3.54M3.97M4.26M4.66M
Other Operating Expenses (Quarter)
7.35M
Operating Expenses (Quarter)
35.36M26.08M25.68M23.17M22.12M21.85M21.56M20.03M24.01M20.86M20.25M22.13M18.13M18.27M15.47M13.42M10.98M17.61M11.26M12.06M
Operating Income (Quarter)
-35.36M-26.08M-25.68M-23.17M-22.12M-21.85M-21.56M-20.03M-24.01M-20.86M-20.25M-22.13M-18.13M-18.27M54.53M-13.42M-10.98M-17.61M-11.26M-12.06M
EBIT (Quarter)
-35.36M-26.08M-25.68M-23.17M-22.12M-21.85M-21.56M-20.03M-24.01M-20.86M-20.25M-22.13M-18.13M-18.27M54.53M-13.42M-10.98M-17.61M-11.26M-12.06M
Non-operating items
Interest & Investment Income (Quarter)
0.78M0.59M0.41M0.39M0.56M0.68M0.62M0.54M0.44M0.32M0.64M0.46M0.52M0.56M0.59M1.12M1.16M1.18M1.02M0.92M
Other Non Operating Income (Quarter)
-0.49M-0.38M-0.23M-0.14M-0.09M0.12M0.06M0.34M0.57M1.12M1.38M1.76M2.06M1.73M1.42M1.74M1.32M1.31M1.20M1.23M
Non Operating Income (Quarter)
0.29M0.21M0.17M0.24M0.47M3.02M0.69M0.88M1.00M1.45M2.02M2.22M2.57M2.29M2.01M2.86M2.48M2.49M2.22M2.15M
Net income details
EBT (Quarter)
-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M-11.26M
Profit After Tax (Quarter)
-35.15M-25.87M-25.51M-22.93M-21.65M-19.00M-20.88M-19.15M-23.01M-17.61M-18.23M-19.91M-15.56M-15.93M56.54M-10.56M-8.33M-15.12M-9.17M-9.94M
Income from Continuing Operations (Quarter)
-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M-11.26M
Consolidated Net Income (Quarter)
-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M-11.26M
Income towards Parent Company (Quarter)
-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M-11.26M
Net Income towards Common Stockholders (Quarter)
-43.00M-26.10M-25.98M-30.05M-57.27M-22.23M-21.99M-30.81M-55.06M-21.61M-20.69M-49.91M-24.98M-18.82M54.02M-12.89M-15.32M-17.57M-11.38M-11.26M
Additional items
EPS (Basic) (Quarter)
-1.19-0.72-0.72-0.83-1.58-0.61-0.60-0.84-1.08-0.49-0.40-0.90-0.44-0.340.95-0.23-0.27-0.31-0.20-0.20
EPS (Diluted) (Quarter)
-1.19-0.72-0.72-0.83-1.58-0.61-0.60-0.84-1.08-0.49-0.40-0.90-0.44-0.340.94-0.23-0.27-0.31-0.20-0.20
Shares Outstanding (Quarter)
36.22M36.19M36.27M36.29M36.35M36.33M36.48M36.52M50.94M43.95M51.81M55.16M56.51M55.03M56.66M56.80M56.93M56.87M57.23M57.37M
Shares Outstanding (Diluted) (Quarter)
36.22M36.19M36.27M36.29M36.35M36.33M36.48M36.52M50.94M43.95M51.81M55.16M56.51M55.03M57.67M56.80M56.93M57.56M57.23M57.37M
Shares Outstanding (Entity) (Quarter)
36.23M36.23M36.29M36.32M36.37M36.43M36.51M36.53M51.64M51.65M52.53M56.41M56.52M56.64M56.68M56.89M56.94M57.14M57.30M57.45M
EBITDA (Quarter)
-35.36M-26.08M-25.68M-23.17M-22.12M-21.85M-21.56M-20.03M-24.01M-20.86M-20.25M-22.13M-18.13M-18.27M54.53M-13.42M-10.98M-17.61M-11.26M-12.06M
Interest Expenses (Quarter)
8.42M0.60M0.70M7.27M35.70M1.05M1.05M11.31M31.49M1.08M1.08M28.25M7.36M1.11M1.11M0.58M5.51M1.14M1.14M0.12M